333 related articles for article (PubMed ID: 18463363)
1. Assessing human papillomavirus vaccine efficacy and safety.
Hendrix SL
J Am Osteopath Assoc; 2008 Apr; 108(4 Suppl 2):S8-S12. PubMed ID: 18463363
[TBL] [Abstract][Full Text] [Related]
2. [Vaccination against human papillomavirus. Implementation and efficacy against cervical cancer control].
Bégué P; Henrion R; Blanc B; Girard M; Sancho-Garnier H
Bull Acad Natl Med; 2007 Dec; 191(9):1805-16; discussion 1816-7. PubMed ID: 18663976
[TBL] [Abstract][Full Text] [Related]
3. Vaccines for the prevention of human papillomavirus and associated gynecologic diseases: a review.
Ault KA
Obstet Gynecol Surv; 2006 Jun; 61(6 Suppl 1):S26-31. PubMed ID: 16729901
[TBL] [Abstract][Full Text] [Related]
4. [Human papillomavirus vaccines].
Brun JL
J Gynecol Obstet Biol Reprod (Paris); 2008 Feb; 37 Suppl 1():S155-66. PubMed ID: 18187268
[TBL] [Abstract][Full Text] [Related]
5. Overview of the clinical development and results of a quadrivalent HPV (types 6, 11, 16, 18) vaccine.
Villa LL
Int J Infect Dis; 2007 Nov; 11 Suppl 2():S17-25. PubMed ID: 18162241
[TBL] [Abstract][Full Text] [Related]
6. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine.
Olsson SE; Villa LL; Costa RL; Petta CA; Andrade RP; Malm C; Iversen OE; Høye J; Steinwall M; Riis-Johannessen G; Andersson-Ellstrom A; Elfgren K; von Krogh G; Lehtinen M; Paavonen J; Tamms GM; Giacoletti K; Lupinacci L; Esser MT; Vuocolo SC; Saah AJ; Barr E
Vaccine; 2007 Jun; 25(26):4931-9. PubMed ID: 17499406
[TBL] [Abstract][Full Text] [Related]
7. Human papillomavirus, cervical cancer, and the vaccines.
Tovar JM; Bazaldua OV; Vargas L; Reile E
Postgrad Med; 2008 Jul; 120(2):79-84. PubMed ID: 18654072
[TBL] [Abstract][Full Text] [Related]
8. Human papillomavirus vaccines.
Schmiedeskamp MR; Kockler DR
Ann Pharmacother; 2006; 40(7-8):1344-52. PubMed ID: 16849621
[TBL] [Abstract][Full Text] [Related]
9. Protecting our patients from HPV and HPV-related diseases: the role of vaccines.
Mahoney MC
J Fam Pract; 2006 Nov; Suppl():10-7. PubMed ID: 17366753
[TBL] [Abstract][Full Text] [Related]
10. AS04-adjuvanted human papillomavirus-16/18 vaccination: recent advances in cervical cancer prevention.
Schwarz TF
Expert Rev Vaccines; 2008 Dec; 7(10):1465-73. PubMed ID: 19053203
[TBL] [Abstract][Full Text] [Related]
11. [HPV vaccination: principles, results and future perspectives].
Rouzier R; Uzan C; Collinet P
J Gynecol Obstet Biol Reprod (Paris); 2007 Feb; 36(1):13-8. PubMed ID: 17293248
[TBL] [Abstract][Full Text] [Related]
12. Impact of baseline covariates on the immunogenicity of a quadrivalent (types 6, 11, 16, and 18) human papillomavirus virus-like-particle vaccine.
Giuliano AR; Lazcano-Ponce E; Villa L; Nolan T; Marchant C; Radley D; Golm G; McCarroll K; Yu J; Esser MT; Vuocolo SC; Barr E
J Infect Dis; 2007 Oct; 196(8):1153-62. PubMed ID: 17955433
[TBL] [Abstract][Full Text] [Related]
13. A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention.
Jenkins D
Gynecol Oncol; 2008 Sep; 110(3 Suppl 1):S18-25. PubMed ID: 18653221
[TBL] [Abstract][Full Text] [Related]
14. Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18.
Villa LL; Ault KA; Giuliano AR; Costa RL; Petta CA; Andrade RP; Brown DR; Ferenczy A; Harper DM; Koutsky LA; Kurman RJ; Lehtinen M; Malm C; Olsson SE; Ronnett BM; Skjeldestad FE; Steinwall M; Stoler MH; Wheeler CM; Taddeo FJ; Yu J; Lupinacci L; Railkar R; Marchese R; Esser MT; Bryan J; Jansen KU; Sings HL; Tamms GM; Saah AJ; Barr E
Vaccine; 2006 Jul; 24(27-28):5571-83. PubMed ID: 16753240
[TBL] [Abstract][Full Text] [Related]
15. New advances in vaccine technology and improved cervical cancer prevention.
Huh WK; Kendrick JE; Alvarez RD
Obstet Gynecol; 2007 May; 109(5):1187-92. PubMed ID: 17470604
[TBL] [Abstract][Full Text] [Related]
16. Introducing human papillomavirus vaccines - questions remain.
Paavonen J; Lehtinen M
Ann Med; 2008; 40(3):162-6. PubMed ID: 18382882
[TBL] [Abstract][Full Text] [Related]
17. Baseline demographic characteristics of subjects enrolled in international quadrivalent HPV (types 6/11/16/18) vaccine clinical trials.
Paavonen J;
Curr Med Res Opin; 2008 Jun; 24(6):1623-34. PubMed ID: 18435868
[TBL] [Abstract][Full Text] [Related]
18. Prevention of human papilloma virus-induced preneoplasia and cancer by prophylactic HPV vaccines.
Hampl M
Minerva Med; 2007 Apr; 98(2):121-30. PubMed ID: 17519854
[TBL] [Abstract][Full Text] [Related]
19. HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine.
Joura EA; Kjaer SK; Wheeler CM; Sigurdsson K; Iversen OE; Hernandez-Avila M; Perez G; Brown DR; Koutsky LA; Tay EH; García P; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Lehtinen M; Steben M; Bosch X; Dillner J; Kurman RJ; Majewski S; Muñoz N; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan J; Lupinacci LC; Giacoletti KE; Lu S; Vuocolo S; Hesley TM; Haupt RM; Barr E
Vaccine; 2008 Dec; 26(52):6844-51. PubMed ID: 18930097
[TBL] [Abstract][Full Text] [Related]
20. The prophylactic role for the human papillomavirus quadrivalent vaccine in males.
Yancey AM; Pitlick JM; Forinash AB
Ann Pharmacother; 2010; 44(7-8):1314-8. PubMed ID: 20501891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
